zadnja posodobitev :
19/11/2024
Antiepileptik   Clonazepam  
Brizgalka
Peroralna raztopina
Stabilnost raztopine Stabilnost mešanice Faktorji, ki vplivajo na stabilnost Kompatibilnost način aplikacije Viri pdf
   Kemična formula  

Lastniško ime   Lastniško ime     

Sestava pomožnih snovi je med paralelami lahko različna

Clonazepamum Poljska
Iktorivil Švedska
Kriadex Mehika
Ravotril Čile
Rivotril Avstralija, Francija, Irska, Kolumbija, Madžarska, Nemčija, Nizozemska, nova Zelandija, Poljska, Savdska Arabija, Španija, Švica, Velika Britanija, Združeni arabski emirati
Viri   Brizgalka   Viri : Clonazepam  
Tip objava
939 časopis Gilbar PJ, Groves CF.
Visual compatibility of total parenteral nutrition solution (Synthamin 17 Premix*) with selected drugs during simulated Y-site injection.
Aust J Hosp Pharm 1994 ; 24: 167-170.
1189 časopis Nation RL, Hackett LP, Dusci LJ.
Uptake of clonazepam by plastic intravenous infusion bags and administration sets.
Am J Hosp Pharm 1983 ; 40: 1692-1693.
1246 časopis Hooymans PM, Janknegt R, Lohman JJHM.
Comparison of clonazepam sorption to polyvinyl chloride-coated and polyethylene-coated tubings.
Pharm Weekbl [Sci] 1990 ; 12: 188-189.
1508 časopis Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.
Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.
EJHP 2015 ;22:123-124.
2115 časopis Schneider JJ, Good Ph, Ravenscroft PJ,.
Effect of tubing on loss of clonazepam administered by continuous subcutaneous infusion.
J Pain Symptom Manage 2006 ; 31, 6: 563-567.
2217 časopis Guchelaar H.J, Hartog M.E.
De stabiliteit van clonazepaminjectievloeistof.
Ziekenhuisfarmacie 1997 ; 13, 1: 21-23.
3184 Traduction Laboratorij
Hyaluronidase (Hyalase®) - Summary of Product characteristics.
CP Pharmaceuticals 2005
3617 Traduction Laboratorij Hyaluronidase (Hyalase®) - Summary of Product Characteristics
Wockhardt 2011
3728 časopis Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.
Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3823 časopis Juan E.P, Palau M.M, Cerd? S.A, Rubert M.A, Nicolau B.R.
Compatibilité physique de médicaments administrés dans l’unité de soins intensifs
Pharmactuel 2015 ; 48, 3 : 146-152.
3976 časopis Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.
Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.
Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218

  Mentions Légales